Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000902252 | SCV001046666 | likely benign | not provided | 2024-12-16 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV001122952 | SCV001281739 | uncertain significance | Congenital microvillous atrophy | 2017-04-28 | criteria provided, single submitter | clinical testing | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases did not allow this variant to be ruled in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. |
Ambry Genetics | RCV002537552 | SCV003592340 | uncertain significance | Inborn genetic diseases | 2024-10-19 | criteria provided, single submitter | clinical testing | The c.1492G>A (p.D498N) alteration is located in exon 12 (coding exon 12) of the MYO5B gene. This alteration results from a G to A substitution at nucleotide position 1492, causing the aspartic acid (D) at amino acid position 498 to be replaced by an asparagine (N). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV003950593 | SCV004761119 | likely benign | MYO5B-related disorder | 2022-02-01 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |